Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is the most common inflammatory skin disease. Recent research findings have provided an insight into the complex pathogenic mechanisms involved in this disease. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are still lacking. Biomarkers of lesional, nonlesional skin, and blood have been developed for baseline as well as after treatment with broad and specific treatments (i.e., cyclosporine A and dupilumab). These biomarkers will help with the development of novel targeted therapeutics and assessment of disease reversal, with the promise of a more personalized treatment approach. Since AD involves more than one subtype (i.e., intrinsic/extrinsic, pediatric/adult, etc.), these molecular fingerprints needs to be validated in all subpopulations with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978 · cited 1×
“The discovery of mutations in the gene encoding filaggrin (FLG) in AD in 2006 [17] led to a theory of FLG mutations as a potential cause of AD, and this temporarily shifted the hypothesis of the primary pathogenic mechanism of AD to one of epithelial barrier dysfunction [18].”
BackgroundLiang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 1×
“IL-22, IL-17, or both may cause the activation of these S100 genes, as these cytokines have been shown to upregulate S100 production in vitro [68,69].”
BackgroundFilaggrin Mutations Associated with Skin and Allergic Diseases
Irvine, A. D., McLean, W. H. I., & Leung, D. Y. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011040 · Cited by 1,217
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200 · cited 1×
“, visual analogue scales [25–28].”
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 12×
“by Th2 and Th22 activation with intensification of these pathways (rather than a switch to a primarily Th1 polarization) in chronic disease, where an increase in Th1-related markers is also seen [7].”
BackgroundSelf-citationNograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627 · cited 1×
“This may be explained by the effects of the IL-22 cytokine [65].”
BackgroundSelf-citationOne remarkable molecule: filaggrin
Brown, S. J., & Irwin McLean, W. H. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.393 · Cited by 527 · cited 1×
“However, only a subset of AD patients (up to 30% to 40%) were found to carry such a mutation, with significantly lower to even absent FLG mutation rates in certain ethnic groups [19–21].”
BackgroundCorrelation of IL-31 serum levels with severity of atopic dermatitis
Raap, U., Wichmann, K., Bruder, M., Ständer, S., Wedi, B., Kapp, A., & Werfel, T. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.05.047 · Cited by 299 · cited 1×
“IL-31 is also increased in the serum of AD patients [43,67], and increased blood levels of this itch-promoting cytokine positively correlate with disease severity [43,44].”
BackgroundBae, J. M., Choi, Y. Y., Park, C. O., Chung, K. Y., & Lee, K. H. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.02.044 · Cited by 201
Atopic dermatitis: a candidate for disease‐modifying strategy
Bieber, T., Cork, M., & Reitamo, S. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02845.x · Cited by 131
Cited by
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Self-citationCellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel, T., Allam, J.-P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky, E., Hoetzenecker, W., Knol, E., Simon, H.-U., Wollenberg, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.010 · Cited by 594
Self-citationEarly-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428
Self-citationAtopic dermatitis and psoriasis: two different immune diseases or one spectrum?
Guttman-Yassky, E., & Krueger, J. G. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.08.008 · Cited by 412
Self-citationMicrobe-host interplay in atopic dermatitis and psoriasis
Fyhrquist, N., Muirhead, G., Prast-Nielsen, S., Jeanmougin, M., Olah, P., Skoog, T., Jules-Clement, G., Feld, M., Barrientos-Somarribas, M., Sinkko, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12253-y · Cited by 409
Metadata
- Authors
- Mansouri, Y., & Guttman-Yassky, E.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2015-04-29
- Volume
- 4
- Issue
- 5
- Pages
- 858-873
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2172165074
- Cited by
- 124
- References
- 12
- FWCI
- 15.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. https://app.cochat.ai/papers/10.3390/jcm4050858
- The paper
- Mansouri, Y., & Guttman-Yassky, E. (2015). Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. Journal of Clinical Medicine. https://doi.org/10.3390/jcm4050858
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.